Mitochondrial eye disease, including forms seen in thymidine kinase 2 deficiency (TK2d), is best managed when recognized early, as timely genetic diagnosis can guide care, improve symptom monitoring and expand access to emerging therapies, according to a review published recently in Progress in Retinal and Eye Research.
Experts emphasized that awareness of eye-related symptoms, such as progressive external ophthalmoparesis, is critical for identifying TK2d before more severe complications develop.
“There is significant evidence that providing patients with a diagnosis has a positive psychological impact, enabling better informed decision-making including appropriate selection of management options and care pathways,” the review’s authors explained.
Mitochondria act as the body’s energy producers, and in TK2d, genetic changes disrupt this energy system. Because the eyes and the muscles that control eye movement require high levels of energy, they are especially vulnerable. This helps explain why progressive external ophthalmoparesis, which causes drooping eyelids and limited eye movement, is a common and often early feature in TK2d and related mitochondrial disorders.
Read more about signs and symptoms of TK2d
Diagnosing TK2d can be challenging. The same genetic change may cause different symptoms in different people, and symptoms can affect multiple organs. In addition, the proportion of affected mitochondrial DNA can vary across tissues, influencing severity of disease. For patients, this means symptoms like vision changes or muscle weakness may appear gradually and differ widely, sometimes delaying diagnosis.
Eye findings in TK2d span a broad range. Progressive external ophthalmoparesis may occur alone or alongside other issues such as muscle weakness, hearing loss or neurologic symptoms. In some cases, retinal changes or optic nerve problems may also develop, affecting vision. Because these symptoms can overlap with other conditions, clinicians must consider mitochondrial disease early when evaluating unexplained eye movement problems.
Genetic testing plays a central role in confirming mitochondrial diseases like TK2d. Identifying the exact mutation helps predict disease course, informs family planning and allows relatives to be tested if needed. It also opens the door to clinical trials and emerging treatments aimed at improving mitochondrial function. For some patients, additional tests such as muscle biopsy or imaging may support the diagnosis.
For patients living with TK2d, this review highlights the importance of paying attention to subtle vision changes and seeking evaluation early. Earlier diagnosis can lead to better symptom management, more personalized care and access to new therapies under development. While no cure currently exists, improved recognition of eye symptoms such as progressive external ophthalmoparesis offers a meaningful step toward better outcomes and quality of life.
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.
